COOKEVILLE, Tenn.--(BUSINESS WIRE)--Aphena Pharma Solutions Inc. is proud to announce that its $20M expansion and renovation, which began mid-2019 in Cookeville, Tennessee, is now complete, adding a large amount of available solid dose packaging capacity.
Aphena Pharma Solutions Inc. completed its $20 million expansion and renovation in Cookeville, TN, adding a large amount of available solid dose packaging capacity.
Aphena is a service provider in the pharmaceutical, OTC, medical device, nbiologics and personal care industries. Through excellence and ninnovation, we provide clients with a full range of packaging and nmanufacturing services, exceeding customers’ expectations through the nuse of leading-edge engineering, technology and project management.
COOKEVILLE, Tenn.--(BUSINESS WIRE)--Aphena Pharma Solutions is proud to announce the launch of its new Third-Party Logistics (3PL) Division, which will be based at the company’s Cookeville, Tennessee, campus. Aphena plans to complete development of the new division by the end of 2021 and to begin serving new 3PL clients in early 2022.
Aphena Pharma Solutions’ ongoing $21 million expansion of its Solid Dose Division in Cookeville, TN, is on schedule with a planned completion date of April 1.
Aphena Pharma Solutions has added cold chain storage and large-scale biologics packaging and distribution in a new, 500,000-sq.-ft. property purpose-built for FDA manufacturing and packaging operations. This new facility is part of the company’s recently announced $21 million expansion of its Solid Dose Division in Tennessee.
SAN DIEGO--(BUSINESS WIRE)--Releviate™ Therapeutics, a bio-pharmaceutical company addressing the needs of patients suffering from chronic pain, signs an exclusive license for two patent pending human monoclonal antibodies developed by researchers at the University of California, Riverside and Duke University. Pre-clinical studies suggest the RLVT-9-01 (anti-MMP-9 antibody) and the RLVT-14-02 (anti-MMP-14 antibody) could directly target the specific matrix metalloproteinases (MMPs) activating neuropathic pain pathways. Extensive recent studies implicate MMP-9, MMP-14 and MMP-2 as causes of chronic pain.
Aphena Pharma Solutions Inc. is investing in a $7 million company-wide expansion for future growth opportunities to be completed by the end of 2019. Targeted expansion areas include additional manufacturing space, custom blending suites, new liquid blending vessels and an additional high-speed bottling line.
Valsartan products not currently recalled - Updated November 27, 2018